Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/81508
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLee, Bonsan Bonneen
dc.contributor.authorToh, Swee-Lingen
dc.contributor.authorRyan, Suzanneen
dc.contributor.authorSimpson, Judy M.en
dc.contributor.authorClezy, Kateen
dc.contributor.authorBossa, Laetitiaen
dc.contributor.authorRice, Scott A.en
dc.contributor.authorMarial, Obaydullahen
dc.contributor.authorWeber, Gerarden
dc.contributor.authorKaur, Jasbeeren
dc.contributor.authorBoswell-Ruys, Claireen
dc.contributor.authorGoodall, Stephenen
dc.contributor.authorMiddleton, Jamesen
dc.contributor.authorTudehope, Marken
dc.contributor.authorKotsiou, Georgeen
dc.date.accessioned2016-06-27T08:30:08Zen
dc.date.accessioned2019-12-06T14:32:34Z-
dc.date.available2016-06-27T08:30:08Zen
dc.date.available2019-12-06T14:32:34Z-
dc.date.issued2016en
dc.identifier.citationLee, B. B., Toh, S. L., Ryan, S., Simpson, J. M., Clezy, K., Bossa, L., et al. (2016). Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial. BMC Urology, 16, 18-.en
dc.identifier.issn1471-2490en
dc.identifier.urihttps://hdl.handle.net/10356/81508-
dc.description.abstractBackground: Urinary tract infections [UTIs] are very common in people with Spinal Cord Injury [SCI]. UTIs are increasingly difficult and expensive to treat as the organisms that cause them become more antibiotic resistant. Among the SCI population, there is a high rate of multi-resistant organism [MRO] colonisation. Non-antibiotic prevention strategies are needed to prevent UTI without increasing resistance. Probiotics have been reported to be beneficial in preventing UTIs in post-menopausal women in several in vivo and in vitro studies. The main aim of this study is to determine whether probiotic therapy with combinations of Lactobacillus reuteri RC-14 + Lactobacillus rhamnosus GR-1 [RC14-GR1] and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 [LGG-BB12] are effective in preventing UTI in people with SCI compared to placebo.en
dc.format.extent8 p.en
dc.language.isoenen
dc.relation.ispartofseriesBMC Urologyen
dc.rights© 2016 Lee et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectUrinary prophylaxisen
dc.subjectMicrobial community profilesen
dc.subjectMulti-resistant organismsen
dc.subjectAntibiotic resistanceen
dc.subjectProbioticsen
dc.subjectBiofilmen
dc.titleProbiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trialen
dc.typeJournal Articleen
dc.contributor.schoolSchool of Biological Sciencesen
dc.identifier.doi10.1186/s12894-016-0136-8en
dc.description.versionPublished versionen
dc.identifier.pmid27084704-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:SBS Journal Articles

SCOPUSTM   
Citations 20

21
Updated on Jul 13, 2024

Web of ScienceTM
Citations 20

14
Updated on Oct 25, 2023

Page view(s) 50

577
Updated on Jul 13, 2024

Download(s) 20

284
Updated on Jul 13, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.